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P/V mutantrt thenon-cytopathic paramyxovirus SimianVirus 5 (SV5),which is a poor inducer of
host cell responses in human tissue culture cells, into a mutant (P/V-CPI−) that induces high levels of apoptosis,
interferon (IFN)-beta, and proinﬂammatory cytokines. However, the effect of SV5-P/V gene mutations on virus
growth and adaptive immune responses in animals has not been determined. Here, we used two distinct animal
model systems to test the hypothesis that SV5-P/Vmutantswhich aremore potent activators of innate responses
in tissue culture will also elicit higher antiviral antibody responses. In mouse cells, in vitro studies identiﬁed a
panel of SV5-P/Vmutants that ranged in their ability to limit IFN responses. Intranasal infection ofmicewith these
WTandP/Vmutantviruses elicitedequivalent anti-SV5 IgG responses at all doses tested, and viral titers recovered
from the respiratory tract were indistinguishable. In primary cultures of ferret lung ﬁbroblasts,WT rSV5 and P/V-
CPI− viruses had phenotypes similar to those established in human cell lines, including differential induction of
IFN secretion, IFN signaling and apoptosis. Intranasal infection of ferretswith a lowdose ofWT rSV5 elicited ~500
fold higher anti-SV5 serum IgG responses compared to the P/V-CPI− mutant, and this correlated with overall
higher viral titers for theWT virus in tracheal tissues. Therewas a dose-dependent increase in antibody response
to infection of ferrets with P/V-CPI−, but not with WT rSV5. Together our data indicate that WT rSV5 and P/V
mutants canelicit distinct innate andadaptive immunity phenotypes in the ferret animalmodel system, but not in
the mouse system. We present a model for the effect of P/V gene substitutions on SV5 growth and immune
responses in vivo.
© 2008 Elsevier Inc. All rights reserved.Introduction
Members of theparamyxovirus family of negative strandRNAviruses
employ a diverse range of mechanisms to circumvent host cell antiviral
responses, including limiting cytokine and type I interferon (IFN) syn-
thesis, blocking IFN signaling pathways and inhibiting apoptosis
(reviewed in Conzelmann, 2005; Garcia-Sastre, 2001; Goodbourn et al.,
2000; Horvath, 2004). Many of these mechanisms for counteracting
cellular responses have been attributed to products of the P/V gene
which typically encodes both the phosphoprotein P subunit of the RNA-
dependent RNA polymerase (Kolakofsky et al, 2004) and the V protein
which counteracts antiviral responses (Didcock et al., 1999a,b; Parisien
et al., 2001). For some paramyxoviruses, the P/V gene also encodes the
family of multifunctional C proteins that are involved in suppressing
antiviral responses and in controlling viral gene expression and virion
release (Devaux and Cattaneo, 2004; Garcin et al., 2001; Lamb and Parks,
2007). For Simian Virus 5 (SV5), accurate transcription of the P/V gene
results in mRNA that codes for the accessory V protein. The P mRNA isl rights reserved.identical to the V mRNA except for the addition of two nontemplated G
residues that are inserted by the viral polymerase at a precise location in
the P/V transcript (Thomas et al.,1988). Thus, theSV5PandVproteins are
identical for the 164 amino-terminal residues (the shared P/V region),
but differ in their C-terminal sequences. The P and V proteins have
unique C-terminal domains, with the V protein encoding a highly
conserved cysteine-rich (cys-rich) zinc-binding domain that is required
for many V-associated functions (He et al., 2002; Paterson et al., 1995).
A major function of the SV5 V protein is the inhibition of IFN
synthesis and signaling (Childs et al., 2007;Didcock et al.,1999a,b; Poole
et al., 2002). During infection of a wide range of animal cells, V protein
forms a cytoplasmic complex that directs the ubiquitylation and tar-
geting of STAT1 (signal transducer and activator of transcription 1) for
degradation (Andrejeva et al., 2002;Ulane et al., 2005). Recently, the SV5
V protein has also been shown to block activation of the IFN-beta
promoter (Heet al., 2002; Poole et al., 2002), throughVprotein targeting
the IFN-inducible RNA helicase mda-5 (Childs et al., 2007) by binding
with the cys-rich region (Andrejeva et al., 2004). Thus, the multi-
functional V protein counteracts IFN responses at two steps, resulting in
both limited induction of IFN synthesis and a block in IFN signaling.
In addition to the cys-rich C-terminal domain, the N-terminal P/V
region of V protein contributes to counteracting host cell antiviral
Fig. 1. Schematic diagram of SV5 viruses used in this study. The genome structures of rSV5-WT, P/V-N100D, WT rSV5-GFP and P/V-CPI− are shown schematically as negative sense
RNA. Only rSV5-GFP and P/V-CPI− encode an additional gene (GFP) inserted between HN and L. The P/V-N100D and P/V-CPI−mutants encode a single N100D mutation or a set of six
CPI−mutations in the shared P/V N-terminal region, respectively. The differences between theWTand CPI− P/V region is shown at the bottomwith stars denoting the residues shown
previously to be important for targeting STAT1 for degradation (Chatziandreou et al., 2002). le, leader; tr, trailer.
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is evident from the naturally-occurring CPI− variant of SV5 which is
defective in targeting STAT1 degradation and in blocking IFN signaling
(Chatziandreou et al., 2002). Mutational analyses have identiﬁed
amino acid differences in the P/V region between WT SV5 and CPI−
that are responsible for defects in targeting STAT1 for degradation
(Chatziandreou et al., 2002). We have previously engineered a re-
combinant rSV5 mutant (P/V-CPI−) to encode these same six CPI− P/VFig. 2.WT and P/V mutant SV5 with differential ability to block IFN signaling in mouse cells.
with pSV-betagal and a plasmid containing the luciferase gene under control of an ISRE. Tw
with WT rSV5 or rSV5-P/V-N100D (panel A) or with rSV5-GFP or rSV5-P/V-CPI− (panel B). A
mouse IFN-beta, after which lysates were prepared and luciferase and Beta-gal assays wer
experiments with bars representing standard deviation from the mean. C) STAT1 levels in P/
WT (W lanes) or P/V-N100D (N lanes). Cell lysates were prepared at the indicated times pi
D) STAT1 phosphorylation. CL7 cells were mock infected or infected at high moi with the indi
beta for 6 h. Cell lysates were analyzed for STAT1, P protein and STAT1 phosphorylated on tsubstitutions in the background of theWT rSV5 genome (Wansley and
Parks, 2002). Our analyses have shown that in human cells, these P/V
gene substitutions converted WT rSV5 into a mutant that could not
induce loss of STAT1 as expected, but the P/Vmutant was also found to
be a potent inducer of IFN and proinﬂammatory cytokines (Wansley
and Parks, 2002; Young et al., 2006).
WT SV5 is unable to effectively block IFN signaling in mouse cells,
and this is due at least in part to the V protein being altered in its(A and B) Differential activation of ISRE-luciferase. Mouse CL7 cells were co-transfected
enty-four hours post-transfection, cells were mock infected or infected at an moi of 20
t 15 h pi, cells were incubated for 6 h with (black bars) or without (grey bars) 1000 U of
e performed. Normalized luciferase activities are representative of three independent
V-N100D infected cells. CL7 cells were mock infected or infected at high moi with rSV5-
and analyzed by Western blotting for levels of STAT1, viral P protein and cellular actin.
cated viruses. At 24 h pi, cells were treated with (+) or without (−) 1000 U of mouse IFN-
yrosine 701 (P-STAT1).
Fig. 3. Differential induction of IFN in mouse cells infected with WT rSV5 and P/V
mutants. A) Induction of the IFN-β promoter. CL7 cells were co-transfected with pSV-
betagal and a plasmid containing the luciferase gene under control of the IFN-beta
promoter. Twenty-four hours post-transfection, cells were mock infected or infected at
highmoiwith the indicated viruses. Cellswere lysed at 15 h pi, and normalized luciferase
activity was calculated as in Fig. 2. Data are the average of three experiments with bars
indicating standard deviation from the mean. B) IFN ELISA. CL7 cells were infected at
high moi with the indicated viruses, and media collected at 24 h pi were analyzed by
ELISA for levels of IFN-beta (grey bars) or IFN-alpha (black bars). Results are the average
of three experiments with bars indicating standard deviation from the mean.
Fig. 4.Multicycle growth ofWTand P/Vmutant SV5 in mouse CL7 cells. Mouse CL7 cells
were infected at an moi of 0.05 with the indicated WT rSV5 or P/V mutants. At the
indicated times pi, media were collected and assayed for infectious virus by plaque
assay. Data are the average of three independent experiments.
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radation (Horvath, 2004). During serial passage of SV5-infectedmouse
tissue culture cells, a viral isolate was identiﬁed (mci-2) which had
gained the ability to block IFN signaling (Young et al., 2001). The
genetic basis for this new phenotype was shown to be a single point
mutation in the shared P/V N-terminal domain at position 100 that
changes an asparagine residue to aspartic acid (N100D). While the
mechanism by which the P/V-N100D mutant blocks mouse IFN sig-
naling was not previously reported, this mutant virus grew to higher
titers than the WT virus in mouse culture cells.
Thestrikingdifferences in cell culturephenotypesof theP/V-CPI− and
the P/V-N100D mutants compared to WT rSV5 raised the question of
whether these viruses would elicit differences in adaptive immune
responses in animals. Our panel of SV5 variants represents viruses that
are poor inducers (WT rSV5 and P/V-N100D) and potent inducers (P/V-
CPI−) of antiviral pathways. Given the role of IFN as an adjuvant (Bracci
et al., 2006; Braun et al., 2002; Fink et al., 2006), we hypothesized that
SV5 variants that induce higher levels of host cell responses would elicit
higher adaptive immune responses, such as anti-SV5 antibodies.
However, given the role of IFN as an inhibitor of virus replication
(Didcock et al., 1999a; Goodbourn et al., 2000), an alternative hypothesis
was that the variants which elicit higher levels of host cell responses
would be restricted for growth, which could in turn lead to lower
antibody titers (Atmar et al., 2007; Braciale et al., 1976; Mak et al., 1982).Herewehave utilized themouse and ferret animalmodel systems to test
these two hypotheses by determining the magnitude and kinetics of
the antibody response to respiratory infection with WT rSV5 and P/V
mutants.
Results
In vitro growth properties of WT and P/V mutant SV5 viruses in
mouse cells
As diagramed in Fig. 1, we employed twomatched pairs of WT SV5
and P/V mutant viruses which differ in their ability to limit host cell
responses. One pair consisted of the P/V-N100D mutant virus, which
can suppress IFN signaling inmurine cells (Young et al., 2001), andWT
rSV5, which cannot block IFN signaling in mouse cells as the proper
control. The second pair consisted of the P/V-CPI− mutant, which is a
potent inducer of antiviral responses, and a WT rSV5 encoding GFP as
an additional transcription unit between HN and L, which was the
proper control virus to account for the GFP gene encoded by P/V-CPI−
(Fig.1;Wansley and Parks, 2002). This additional gene has been shown
previously to have no detectable effect on rSV5 growth properties (He
et al., 1997).
To determine the relative ability of WT and the two P/V mutants to
modulate IFN-I signaling, mouse CL7 ﬁbroblast cells were transfected
with a luciferase reporter gene plasmid under control of an ISRE and
then infected at high moi with WT rSV5 or one of the P/V mutants.
Fifteen hours pi, cells were challenged with 1,000 units of IFN-beta, and
luciferase activitywas assayed at 6 hpost-challenge. As shown in Fig. 2A,
mock-infected cells responded to IFN challenge by increasing luciferase
activity (black bar). Cells infected with rSV5-WT also responded to IFN
challenge with slightly higher levels of luciferase activity, but cells in-
fected with the P/V-N100D mutant were largely non-responsive to IFN
419G.A. Capraro et al. / Virology 376 (2008) 416–428stimulation (Fig. 2A) as previously reported (Young et al., 2001). As
shown in Fig. 2B, cells infectedwith the P/V-CPI− virus showed elevated
IFN-I signaling with or without added IFN-beta, similar to that reported
previously for P/V-CPI− infection of human epithelial cells (Wansley and
Parks, 2002).
The status of STAT1 inmouse cells infectedwithourWTrSV5andP/V
mutant viruses was analyzed. CL7 cells were infected at high moi
with rSV5-WT or P/V-N100D, and cell lysates were analyzed at dif-
ferent times pi byWestern blotting. As shown in Fig. 2C, cells infected
with rSV5-WT had higher levels of STAT1 than mock-infected cells,
consistent with IFN induction and signaling pathways being ac-
tivated. By contrast, infection with the P/V-N100D mutant did not
signiﬁcantly change STAT1 levels compared to that seen for mock-
infected cells. Immunoﬂuorescence microscopy conﬁrmed that all
cells were infected by the P/V-N100D virus at the high moi used in
these experiments (not shown).
Infection with the P/V-N100D virus blocked the ability of ex-
ogenously-added IFN-beta to activate STAT1 phosphorylation. This is
evident in Fig. 2D, where treatment of mock-infected or rSV5-WT-
infected CL7 cells with IFN-beta resulted in phosphorylation of STAT1Fig. 5. Effect of virus dose on antibody responses in mice infected with WT SV5 and P/V-N10
rSV5 (closed diamonds) or P/V-N100D (open squares). At days 14 and 21 pi sera were collect
were boosted with an equivalent amount of homologous virus, and levels of anti-SV5 antibod
individual mouse with the horizontal bar indicating the mean value for the group.on tyrosine 701, a criticalmodiﬁcation for STAT1 activation (Shuai et al.,
1993). By contrast, treatment of P/V-N100D-infected mouse cells with
IFN-beta did not lead to increased STAT1 phosphorylation. Together,
these data support previous reports (Young et al., 2001) that mouse
cells infected with the P/V-N100D virus are defective in response to
IFN, but extend those ﬁndings to show that the P/V-N100D mutant
blocks STAT1 phosphorylation by a mechanism that does not include
targeted degradation.
The data in Figs. 2A and B (grey bars) show that murine cells
infected with rSV5-WT, rSV5-GFP or the P/V-CPI− mutant have ac-
tivated IFN signaling pathways, even in the absence of exogenously-
added IFN. To test the hypothesis that infection with these viruses
induced IFN, CL7 cells were transfected with a luciferase reporter
gene plasmid under control of the IFN-beta promoter and infected at
high moi with the viruses indicated in Fig. 3A. Levels of luciferase
were determined at 15 h pi. Infectionwith the two viruses encoding a
WT P/V gene (rSV5-WT and rSV5-GFP) resulted in a ~2–3 fold in-
crease in IFN-beta promoter activity, whereas cells infected with the
P/V-CPI− virus showed nearly a 10 fold increase. By contrast, cells
infected with the P/V-N100D mutant showed luciferase levels that0D. Groups of 5 BALB/c mice were infected i.n. with the indicated doses (in pfu) of WT
ed and assayed by ELISA for anti-SV5 IgG1 (panel A) and IgG2a (panel B) responses. Mice
ies were determined at day 4 and day 23 post boost. Each symbol represents data for an
Fig. 6. Growth ofWTand P/Vmutant rSV5 inmice. Groups of BALB/cmice were infected
i.n. with 106 pfu of rSV5-WTor P/V-N100D (panels A and C) orwith rSV5-GFP or P/V-CPI−
(panel B). At the indicated days pi, lungs (panels A and B) or nasal tissue (panel C) were
harvested and assayed for infectious virus by plaque assay as described in Materials and
methods. Data are the average of three mice per time point, with bars representing the
standard deviation from the mean.
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These results were supported by ELISA data, in which levels of se-
creted IFN-beta and IFN-alpha were determined at 24 h pi. As shown
in Fig. 3B, the P/V-CPI− mutant induced slightly higher levels of IFN-
beta than either the rSV5-WTor rSV5-GFP viruses. However, the P/V-
N100D mutant was a poor inducer of IFN-beta. The P/V-CPI− mutant
was the only virus that induced high levels of IFN-alpha.
Taken together, these results demonstrate thatWT SV5 and the P/V
mutants fall into two groups: 1) the P/V-N100Dmutant virus, which is
a poor inducer of IFN and limits IFN signaling, and 2) the P/V-CPI−
mutant,which, likeWTrSV5-GFP, is defective in blocking IFN signaling,
but which additionally is a potent inducer of IFN, as it induces IFN to
higher-than-WT levels. As predicted by these properties, the P/V-
N100D virus grew in CL7 cells to titers that were approximately 2 logs
higher in multi-step growth assays (Fig. 4A). Unexpectedly however,
the P/V-CPI− virus grew tohigher titers than rSV5-GFP (Fig. 4B), despite
being a more potent activator of IFN responses. This enhanced growth
may be a consequence of higher levels of viral gene expression and
genome replication as described previously in human epithelial cell
lines (Wansley and Parks, 2002).
Virus growth and antibody responses to i.n. infection of mice with WT or
P/V mutant SV5
Based on our in vitro data above, we tested the hypothesis that
intranasal (i.n.) infection of mice with these mutant viruses would
elicit different antibody titers. Groups of ﬁve mice each were infected
i.n. with increasing doses (104, 105, 106 or 107 pfu) of puriﬁedWT rSV5
or P/V mutant viruses and boosted with an equivalent amount of the
homologous virus on day 21 pi. Infected animals showed no clinical
signs of illness and pathological lesions in the nasal cavities weremild,
consisting of inﬁltration by mixed type inﬂammatory cells, superﬁcial
epithelial injury and edema (data not shown). At the days pi shown in
Fig. 5, sera were collected and used in an SV5-speciﬁc ELISA to
determine the titers of IgG1 and IgG2a. These isotypes were chosen
because they are indicative of the CD4+ TH cell response to virus
infection (Finkelman et al., 1990), and therefore provide an internal
control to our experiment that would ensure wewere not missing any
portion of the antibody response because of a missing TH1 or TH2
population. There was a dose-dependent increase in the anti-SV5 IgG1
(Fig. 5A) and IgG2a (Fig. 5B) isotype response following i.n. infection of
mice with doses between 104 and 106 pfu, and the highest dose of
virus yielded ﬁnal titers that were nearly 100-fold higher than the low
dose of virus. A dose of 107 pfu did not signiﬁcantly increase responses
over that seen with 106 pfu. Most importantly however, there was no
difference in antibody titers elicited with the WT rSV5 parental virus
and P/V-N100D virus. Similarly, there was no difference in the
antibody responses elicited by rSV5-GFP compared to the P/V-CPI−
mutant (data not shown).
We tested the hypothesis that the similar antibody response in
mice toWTand P/Vmutant infectionwas due to similar in vivo growth.
Groups of BALB/cmicewere infected i.n. with 106 pfu of virus, and viral
titers in tissues from the lungs were determined at various times pi. As
shown in Fig. 6A, mice infected with rSV5-WT or the P/V-N100D
mutant virus showed high titers of virus at early times pi, with a
plateau between 3 and 7 days pi. A very similar proﬁle of virus titers
was seen in the case of mice infected with the rSV5-GFP and P/V-CPI−
mutant viruses (Fig. 6B). WT rSV5 and P/V mutants grew to higher
titers and virus was recovered at later times pi in nasal tissues com-
pared to lung tissues; however, there were no differences in virus
growth between animals infected with either virus (Fig. 6C). Together,
these data indicate that infection of mice with rSV5 viruses that differ
in their ability to induce IFN does not result in differences in levels
of virus recovered from the respiratory tract, and there is no dose-
dependent difference in anti-SV5 antibody responses elicited in mice
by the WT and P/V mutants.Growth properties of rSV5-GFP and P/V-CPI− viruses in primary cultures
of ferret lung ﬁbroblasts
It has been previously reported that SV5 is restricted for growth in
mice (Parisien et al., 2002; Young et al., 2001). As an alternative
animal model to test our hypotheses, we turned to the ferret system,
which has been used as a model for studying a number of respiratory
virus infections (Durchfeld et al., 1991; von Messling et al., 2003;
Zitzow et al., 2002). In this model system, the P/V-N100D mutant
virus becomes irrelevant, since this virus has phenotypes that are
speciﬁc for the mouse system. Primary cultures of lung ﬁbroblasts
were established from naïve ferrets as described in Materials and
methods. Staining with anti-cytokeratin antibodies showed these
cells were N95% ﬁbroblasts (data not shown). To determine the
growth properties of WT SV5 and P/V-CPI− in ferret cells, cultures
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andGFP expression. As shown in Fig. 7A, very low levels of NP andGFP
were detected at 12 h pi, but were greatly enhanced by 24 h pi. In
multi-step growth analyses, the P/V-CPI−mutant grew to a ﬁnal titer
that was ~1 log lower than rSV5-GFP (Fig. 7B), consistent with our
previous results with human tissue culture cell lines (Wansley and
Parks, 2002). It is noteworthy that titers of both WT and P/V mutant
SV5 in the ﬁbroblast cells shown in Fig. 7B were ~2 logs lower than
that seen in human epithelial cells (Wansley and Parks, 2002). This is
consistent with our ﬁndings that SV5 yields in many ﬁbroblast cell
lines are typically much lower than that seen in epithelial cells (data
not shown).
To determine the effect of WT SV5 and P/V-CPI− infection on
ferret STAT1, ferret cells were infected at high moi with rSV5-GFP or
P/V-CPI−, and cell lysates were analyzed by Western blotting for
levels of STAT1. Consistent with our previous results from human
cells (Wansley and Parks, 2002), WT infection induced the rapid
degradation of STAT1, and by 12 h pi there was little detectable STAT1
(Fig. 7C). By contrast, ferret cells infected with the P/V-CPI− mutant
virus showed no signiﬁcant loss of STAT1. STAT1 was activated fol-
lowing infection of ferret cells with P/V-CPI− but not WT SV5. This is
evident in Fig. 7D where cell lysates were analyzed by Western
blotting for phosphorylation of STAT1 on residue tyrosine 701 as an
indication of IFN signaling. These data are consistent with in vitro
results with human cell lines, and suggest that IFN is induced by
infection with the P/V-CPI− mutant.
An RPA was carried out to determine if ferret IFN-beta was dif-
ferentially induced by WT rSV5 and the P/V-CPI− mutant. A cDNA
encoding ferret IFN-beta was generated by RT-PCR using RNA fromFig. 7. In vitro growth properties of rSV5-GFP and P/V-CPI−mutant in ferret lung ﬁbroblast c
infected at an moi of 10 with rSV5-GFP or P/V-CPI−. Cell lysates prepared at the indicated tim
moi growth analysis. Ferret cells were infected with rSV5-GFP or P/V-CPI− at an moi of 0.05
representative of four independent experiments. C and D) STAT1 status in ferret ﬁbroblasts. P
10 with WT rSV5-GFP (WT lanes) or the P/V-CPI− mutant (C lanes). At the indicated times p
phosphorylated on tyrosine 701 (P-STAT1), viral P protein or cellular actin as indicated. E) IFN
infected (M lane) or infected at an moi of 10 with rSV5-GFP (WT lanes) or P/V-CPI− and analy
beta. Results are representative of three independent experiments.naïve ferret lung ﬁbroblasts, as described in Materials and methods.
RNA was harvested at 20 h pi with WT rSV5-GFP or the P/V-CPI−
mutant and was analyzed using a negative sense 32P-labeled ferret
IFN-beta riboprobe. As shown in Fig. 7E, samples from P/V-CPI−
infected cells yielded a protected band consistent with IFN-beta
mRNA expression, while no signals were seen in the case of RNA from
mock-infected or rSV5-GFP infected cells. These results are consis-
tent with previous results obtained in human cells showing induc-
tion of IFN-beta expression by the P/V-CPI− mutant (Wansley and
Parks, 2002).
To determine the CPE following infection of ferret ﬁbroblasts, cells
were infected at high moi with rSV5-GFP or P/V-CPI− and examined at
48 h pi bymicroscopy. As shown in Fig. 8A, ferret cells infectedwith the
rSV5-GFP virus showed very little CPE similar to that seenwith mock-
infected cells. By contrast, ferret cells infected with the P/V mutant
virus showed extensive CPE. Cell viability assays (Fig. 8B) showed that
cell cultures infected with rSV5-GFP had very little loss of viability. P/V
mutant-infected ﬁbroblasts showed a time-dependent loss of viability
starting at ~48 h pi, and by 72 h pi very few viable cells were detected.
The loss of viability in P/V-CPI− infected ferret cells correlated with
increased levels of annexin V staining. This is evident in Fig. 8C, where
rSV5-GFP infection resulted in a very low percentage of cells that were
positive for annexinV staining. By contrast, ~65% of ferret cells infected
with the P/V-CPI−mutantwere positive for annexin V by 48 h pi. Taken
together, the above data indicate that infection of primary cultures of
ferret lung ﬁbroblasts with WT and P/V mutant SV5 reproduces a
number of phenotypes of infected human cells, including multi-step
growth kinetics and differential activation of IFN pathways (Fig. 7), and
apoptosis (Fig. 8).ells. A) GFP expression. Primary cultures of ferret ﬁbroblast cells were mock infected or
es pi were analyzed by western blotting for viral NP and GFP or for cellular actin. B) Low
. Media were collected at the indicated times pi for analysis by plaque assay. Data are
rimary cultures of ferret ﬁbroblasts were mock infected (M lane) or infected at an moi of
i, cell lysates were prepared for analysis by Western blotting for cellular STAT1, STAT1
-β gene expression. RNAwas harvested at 20 h pi from ferret ﬁbroblasts that were mock
zed by RPA using a 32P-radiolabeled anti-sense riboprobe (P lane) speciﬁc for ferret IFN-
Fig. 8. Induction of CPE and apoptotic markers following infection of ferret ﬁbroblasts with the P/V-CPI−mutant but not rSV5-GFP. A) Ferret ﬁbroblasts weremock infected or infected
at an moi of 10 with WT rSV5-GFP or the P/V-CPI− mutant. Cells were examined by microscopy at 48 hours pi for CPE and GFP expression. B) The number of viable cells at the
indicated times pi was determined by trypan blue exclusion. Data are expressed as fold change in viable cell number compared to the starting number of cells and are the average of 3
samples per timepoint. Bars represent standard deviation from the mean. C) Cells were analyzed by ﬂow cytometry at the indicated times pi for staining with PE-conjugated annexin
V. Data are the average of 3 samples per timepoint, with bars representing the standard deviation from the mean.
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P/V mutant
Based on the above in vitro data in primary ferret ﬁbroblasts, we
tested the hypothesis that i.n. infection of ferrets with these viruses
would elicit different antibody titers. Ferrets had no detectable
preexisting antibodies that recognized SV5 in ELISAs (not shown).
Groups of three ferrets each were infected i.n. with increasing doses(104, 106 or 108 pfu) of puriﬁed rSV5-GFP or P/V-CPI− virus and
boosted with an equivalent amount of the homologous virus on
day 28 pi. Infected animals showed no clinical signs of illness, and
pathological lesions in the nasal cavities included minimal sub-
mucosal edema and small amounts of luminal hemorrhage. Sig-
niﬁcant lesions were not found in the lung or brain (data not shown).
Thus, infection of ferrets with SV5 doses as high as 108 pfu was well
tolerated.
Fig. 9. Antibody response and viral titers elicited by intranasal infection of ferretswith rSV5-GFP and P/V-CPI−. A and B) ELISA and neutralizing antibody titers. Groups of 3 ferrets each
were infected i.n. with 104, 106, or 108 pfu of rSV5-GFP or P/V-CPI−. At day 28 pi, serumwas collected and ferrets were boosted with an equivalent amount of homologous virus. Levels
of anti-SV5 antibodies in serum fromday 28 and d14 post boost (panel A) and neutralizing titers in d28 and d14 post boost serum (panel B) were determined as described inMaterials
and methods. Each symbol represents data for an individual ferret with the horizontal bars indicating the mean value for the group. Results are representative of two independent
experiments. C) Viral titers. Ferrets were infected i.n. with 104 pfu of rSV5-GFP or P/V-CPI−, and viral titers in the upper trachea of animals were determined at the indicated days pi.
Each symbol represents the titer for one experimental animal, and the bar represents the mean value for the group.
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post boost (pb) were assayed for levels of SV5-speciﬁc IgG by ELISA as
described in theMaterials andmethods. As shown in Fig. 9A, ferrets that
received the P/V-CPI− virus showed a dose-dependent increase in anti-
SV5 antibody titers following the primary infection (left panel, open
boxes),withmean titers reaching~104 at thedoseof 108 pfu. Bycontrast,
ferrets that received rSV5-GFP (closed diamonds, Fig. 9A) showed the
highestmeananti-SV5 titerswith the lowest doseof virus in theprimary
infection (104). With increasing doses of rSV5-GFP there was a slight
decrease in titer that was statistically signiﬁcant (p=0.001). Most
importantly, at the lowest dose of virus (104 pfu), rSV5-GFP elicited a
mean antibody titer that was ~500 fold higher than that elicited with
the P/V-CPI− virus, and this difference was statistically signiﬁcant (p=
0.0002). With increased doses of 106 and 108 pfu, the P/V-CPI− mutant
elicited higher antibody titers, whereas rSV5-GFP elicited lower titers.
Mean antibody titers to rSV5-GFP and the P/Vmutant at 106 and 108 pfu
were not statistically different. Thus, in the primary infection, a lowdose
of rSV5-GFP ismore effective than the P/V-CPI−mutant at inducing anti-
SV5 antibody responses. At higher doses, there is an increased response
to P/V-CPI− and a slightly decreased response to rSV5-GFP such that the
antibody responses are now equivalent.
Ferrets responded differently to boosting with WT rSV5-GFP and
P/V-CPI− mutant. This is evident in Fig. 9A (right panels), where
antibody responses to the P/V mutant increased signiﬁcantly when
animals were given a low or intermediate dose (pb0.05 for both
doses). There was only a slight increase in antibody titers at the high
dose, which was not statistically signiﬁcant. By contrast, boosting
with the WT rSV5-GFP virus did not signiﬁcantly increase antibody
titers. As shown in Fig. 9B, neutralizing Ab titers elicited by P/V-CPI−
were slightly lower than WT rSV5-GFP; however, they did not differ
signiﬁcantly from each other at any dose tested.
To determine if the difference in ferret anti-SV5 responses at low
dose correlated with differences in virus growth in vivo, groups of
ferrets were infected i.n. with 104 pfu of rSV5-GFP or P/V-CPI−, and the
trachea and lungs were assayed for virus levels by plaque assay at days
2, 4, 6, and 11 pi. No virus was detected in samples from the lower
trachea or in ferret lungs (not shown). However, in samples from the
upper trachea, viral titers from animals infected with rSV5-GFP were
approximately one log higher than those seen for animals infected
with the P/V-CPI−mutant (Fig. 9C). These data are consistent with the
hypothesis that at the lowest dose, virus replication is higher for WT
virus compared to the P/V mutant, which contributes to eliciting a
higher anti-SV5 antibody titer.
Discussion
The goal of this study was to utilize the mouse and ferret animal
model systems to test the hypothesis that SV5 P/V genemutantswhich
are more potent activators of cell responses in tissue culture will also
be better at eliciting adaptive immune responses. This hypothesis was
based on our previous work showing that: 1) the P/V-CPI−mutant was
more effective than WT rSV5 at activating innate responses in cell
culture (Wansley and Parks, 2002), and 2) human DC infected with the
P/V-CPI− virus are more effective at activating T cell functions in vitro
than DC infected with WT rSV5 (Arimilli et al., 2006). Likewise, it has
been proposed that viruses encoding defective antagonists of antiviral
responses would be more effective vectors for eliciting adaptive im-
munity (Talon et al., 2000; Valarcher et al., 2003). Here we show that
primary cultures of ferret lung ﬁbroblasts reproduce many of the in
vitro human cell culture properties of WT SV5 and P/V-CPI− described
previously, including differences in STAT1 degradation, induction of
IFN synthesis and signaling, and CPE. Most importantly for our hy-
pothesis, low dose intranasal infection of ferrets with WT and P/V
mutant SV5 elicited different antibody responses, and different levels
of virus were recovered from the ferret trachea. By contrast, in the
mousemodel systemWTand P/Vmutants showed differences in theirability to counteract IFN responses in tissue culture cells, but intranasal
infection of mice with these mutants did not result in differences in
either virus growth or antibody responses at any dose tested. Together,
these data support the proposal that ferrets represent an excellent
animal model system for in vivo analysis of SV5 growth and immune
responses.
SV5 infection efﬁciently targets STAT1 for degradation in human
cell lines (Didcocket al.,1999b; Younget al., 2000), and in tissue culture
cells from a number of other species includingmonkey, dog, and horse,
but not rabbit cells (Precious et al., 2005). In our primary cultures of
ferret cells, WT SV5 efﬁciently targeted ferret STAT1 for degradation,
whereas the P/V-CPI− mutant which is defective for this property in
human cells (Wansley and Parks, 2002) is also defective in STAT1
degradation in ferret cells. Furthermore, our results show that the P/V-
CPI− mutant virus induced higher levels of IFN-beta mRNA than WT
rSV5, consistent with this mutant virus being defective in limiting IFN
induction in ferret cells. The inability to limit IFN induction and sig-
naling pathways likely contributes to the P/V-CPI−mutant virus having
attenuated low moi growth in ferret cells compared to WT SV5, a
property also seen during infections of human tissue culture cells
(Wansley et al., 2005). These ﬁndings raised the hypothesis that
differences in the ability of WT SV5 and P/V-CPI− to limit ferret cell
antiviral responses would be reﬂected in vivo by differences in adap-
tive responses to infections of the ferret respiratory tract.
The ferret is a widely-used animal model for studying viral
infections (Rudd et al., 2006; Silin et al., 2007; Svitek and vonMessling,
2007; von Messling et al., 2006; Yen et al., 2007). Ferrets are highly
susceptible to a number of experimental viral respiratory infections,
including inﬂuenza virus (Zitzow et al., 2002), canine distemper virus
(CDV; Hoover et al., 1989; Svitek and von Messling, 2007), and SARS-
associated corona virus (Martina et al., 2003). In the case of CDV,
infected ferrets show massive dissemination of virus throughout the
body, with excessive morbidity and mortality (von Messling et al.,
2003). In our studies, infection of the ferret respiratory tract with WT
SV5 or the P/V-CPI−mutant resulted in no overt indication of illness—
animals remained playful with no changes in either body weight or
temperature. Likewise, analyses of respiratory tract tissues did not
provide any evidence of virus-induced pathology (data not shown).
These results are consistent with previous work examining the pa-
thology of the bone ﬁde CPI virus in ferrets (Baumgartner et al., 1989,
1991), and with a mouse model system in which SV5 was only path-
ogenic under conditions in which immune responses were severely
compromised, such as in STAT1-deﬁcientmice (He et al., 2002; Randall
and Young, 1991).
A low dose of only 104 pfu of WT rSV5 was sufﬁcient to elicit a
strong anti-SV5 antibody response, and virus was recovered from the
trachea of infected animals up to 6 days after infection. For both WT
and P/Vmutant SV5, virus was detected in tissue from the ferret upper
trachea, but there was no detectable virus in tissues from the lung or
lower trachea as described previously for CPI infections of ferrets
(Durchfeld et al., 1991). Importantly, at a low dose of 104 pfu the P/V-
CPI−mutant elicited ~500 fold lower anti-SV5 antibody response than
that seen with the same dose of WT virus. In addition, the antibody
response to P/V-CPI− infection increased as the dose was increased
between 106 and 108 pfu, whereas this was not seen with WT rSV5.
Finally, with P/V-CPI−, the anti-SV5 antibody titer was increased by ~1
log following a secondary infection, whereas anti-SV5 responses were
not altered following a booster infection with WT rSV5. Future work
will focus on whether there is also a dose-dependent difference in
cellular immune response to these two viruses, but this will require
the development of appropriate ferret-speciﬁc reagents for cellular
immunology.
Why is the antibody response to low dose infection with the P/V-
CPI− mutant so much lower than that elicited by the WT SV5 virus?
One of our original hypotheses was that the P/V-CPI− virus, which
induces DC maturation and is defective in limiting cytokine induction
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bodies, possibly due to the positive effects of innate cytokines on
adaptive immune responses (Bracci et al., 2006; Braun et al., 2002;
Fink et al 2006). As an alternative hypothesis, the induction of innate
responses to P/V-CPI− could limit virus replication, which in turn
could limit the antibody responses. Our results are consistent with
the second hypothesis, since i.n. infection with the P/V-CPI− mutant
elicited lower antibody titers than that seen with WT rSV5 and lower
levels of virus were recovered from the ferret respiratory tract. At
higher doses of both viruses, we hypothesize that there is an increase
in either the number or type of infected cells. In the case of the P/V
mutant, this could overcome limitations in viral replication seen at the
lower doses, resulting in higher antibody titers. With WT rSV5, we
have shown that higher doses elicited slightly lower anti-SV5 anti-
bodies, possibly due to different cell types being infected. Future work
will focus on directly determining the levels of viral antigen and
replication following infection with different doses of WT and P/V
mutant SV5.
It is possible that ferret dendritic cells (DC) play a role in the
antibody response to SV5 infection, since DC play a critical role in
linking the innate and adaptive arms of the immune response to
pathogens (Palucka and Banchereau, 1999). Our previous cell culture
studies have shown that apoptosis is induced in human immature
dendritic cells infected with WT rSV5, but not with the P/V-CPI−
mutant (Arimilli et al., 2006, 2007). Likewise, DC infectedwith the P/V-
CPI− mutant are more effective activators of T cell functions than DC
infected with WT rSV5 (Arimilli et al., 2006). The role that DC plays
in different ferret antibody proﬁles elicited by WT SV5 and the P/V
mutant has not yet been evaluated. Anti-SV5 responses could be
the result of DC acquiring antigen by direct infection or by cross-
presentation. In the former case, differences in dose-dependent anti-
body responses toWTand P/Vmutant SV5 could be explained by ferret
DC beingmore readily infected in vivo at high rather than at low doses
of virus. In the case of the P/Vmutant, higher doses could lead tomore
infected DC and to a higher anti-SV5 response. In the case of WT SV5,
higher doses could lead to virus-induced apoptosis of infected DC, and
this could contribute to the slight decrease in antibody responses
compared to the P/V-CPI− virus. Further experimentation is required to
test this proposed mechanism involving ferret DC.
Interestingly, ferrets given a lowdose of 104 pfu of P/V-CPI− showed
lower total antibody responses compared to rSV5-GFP when assayed
byELISA, but the neutralizing titers elicited by the twoviruseswere not
statistically different. This result may indicate that total antibody
responses to SV5 proteins are higher in the case of WT rSV5-GFP
consistent with higher replication, but antibody responses to surface
HN and F are similar. Alternatively, levels of anti-HN or -F antibodies
elicited by the P/V mutant may be low, but could be superior in their
capacity for neutralization compared to higher levels elicited by rSV5-
GFP, perhaps due to the adjuvant effect of cytokines elicited by the P/V
mutant. Work is in progress to determine the anti-HN and anti-F
responses elicited by WT and P/V mutant viruses, and the relative
avidity of these antibodies.
In mouse cells, WT SV5 cannot target STAT1 for degradation
(Young et al., 2001) and this is thought to be due to an inability of V
protein to properly interact with murine STAT2 (Parisien et al., 2002;
Precious et al., 2005). Most importantly for our hypotheses on innate
and adaptive immunity, we have analyzed a previously identiﬁed SV5
P/V mutant (N100D) with a gain-of-function ability to block IFN sig-
naling in mouse tissue culture cells (Young et al., 2001). We have
extended this ﬁnding to show that the P/V-N100D virus prevents
phosphorylation of STAT1 in response to exogenously-added IFN by an
undetermined mechanism, but STAT1 levels do not appear to differ
from that of mock-infected cells.
Here we show that the P/V-CPI− mutant is a very potent inducer of
both IFN-beta and IFN-alpha in mouse cells, compared to the moderate
induction of IFN-beta following WT rSV5 infection. Unexpectedly how-ever, the P/V-N100D virus was found to be a poor inducer of IFN syn-
thesis. Thus, the change of asparagine residue 100 to aspartic acid in the
PandVproteins confers twonewphenotypes onWTrSV5: a block in IFN
signaling as shown by Young et al. (2001) and lower induction of IFN
secretion. More detailed work is needed to uncover the mechanism by
which the N100D mutation alters the ability of SV5 to limit IFN pro-
duction. For the purposes of this study, our cell culturework identiﬁed a
panel ofWTand P/Vmutantswith decreasing ability to limitmurine IFN
induction and signaling pathways: N100DNWT rSV5NP/V-CPI−.
Our results with antibody responses to WT and P/V mutant SV5 in
the mouse system differ signiﬁcantly from that of the ferret system.
Following i.n. infection of mice, anti-SV5 antibody responses were
similar between WT SV5 and each of our P/V mutants at all doses
tested. Likewise, there was no detectable difference in levels of virus
recovered from mice infected with any of the SV5 viruses. These data
indicate that there are restrictions on virus growth in the murine
respiratory tract that are not evident in our cell culture system, and
that they are independent of any differences in P/V mutations. It is
unlikely that these restrictions are due exclusively to IFN, since the
growth of WT SV5 and P/V-CPI− in mice deﬁcient in the IFN receptor
(IFNAR−/− mice) was very similar and was not signiﬁcantly enhanced
over normal mice (data not shown). In this regard, there may be
species speciﬁc restrictions in SV5 replication in murine cells, since
the yield of SV5 progeny from CL7 mouse tissue culture cells is ~100–
1000 fold lower that that typically seenwith human cell lines in vitro.
Kraus et al. (2008) have recently reported a transgenic mouse
system in which WT rSV5 can induce STAT1 degradation and block IFN
signaling. In these human STAT2 transgenic (hSTAT2 Tg) mice, WT rSV5
grows to ~100 fold higher titer in the respiratory tract compared to
normal control mice (Kraus et al., 2008). Why is virus replication en-
hanced in the case of WT SV5 infection of hSTAT2 Tg mice compared to
normalmice, but the N100Dmutant, which is a poor inducer of IFN and
blocks IFN signaling, grows to titers that are similar to WT rSV5? One
possibility is that there may be added beneﬁt to virus replication by
degrading STAT1 in the case ofWT rSV5-infected hSTAT2 Tgmice versus
blocking STAT1 phosphorylation as our data indicate for the P/V-N100D
mutant. In this regard, there is evidence that STAT1 may serve as a
constitutive transcription factor for basal expression of some cellular
genes (reviewed in Horvath, 2000), and virus replication in vivo may be
enhanced when this function is eliminated due to STAT1 degradation. A
secondpossibility is that lymphocytes recruited to the site of infection in
hSTAT2 Tgmicemay differ in their capacity tomount antiviral responses
compared to control normalmice. Ananalysis of the effector functions of
lymphocytes in the hSTAT2 Tgmouse and P/V-N100D systemsmay shed
light on this proposal.
In summary, at low doses an SV5 P/V gene mutant that is a potent
inducer of IFN in tissue culture cells grows to lower titers and is less
effective than WT SV5 in eliciting antiviral antibody responses in the
ferret model system. This contrasts with results from the mouse
model systemwhere P/V mutants and WT SV5 show no differences in
growth in the respiratory tract or in anti-SV5 antibody responses,
despite their abilities to induce IFN. However, in both systems, the
level of in vivo growth correlated with the level of antibody produced.
Materials and methods
Cells, viruses, growth analysis and plaque assays
MouseCL-7 cellswere grown inDulbecco'smodiﬁedEagle'smedium
(DMEM) containing 10% fetal bovine serum (FBS). Primary lung cell
culturesweremade fromnaïve sable ferrets. The lungswere excised and
washed three times in sterile phosphate-buffered saline (PBS). Lungs
were minced into small pieces (~1 mm), and FBS was added drop-wise
to each piece. Minced lung pieces were mashed and cultured for 4 h
at 37 °C, followed by the addition of DMEM containing 20% FBS, and
further culturinguntil growth to conﬂuence. Todetermine thepercentof
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vimentin antibody (Santa CruzBiotechnology) followedby stainingwith
an anti-goat IgG antibody conjugated to AlexaFluor 468 and visualized
by ﬂuorescent microscopy.
AWT rSV5 and rSV5 expressing GFP (He et al., 1997) were recovered
as described previously (Parks et al., 2002) from cDNA plasmids kindly
provided by Robert Lamb (Northwestern University) and Biao He (Penn
State University). The P/V-N100Dmutant virus (Young et al., 2001) was
provided by BiaoHe andwas grown inMDBK cells. The P/V-CPI−mutant
was recovered from cDNA and grown in Vero cells as described pre-
viously (Wansley and Parks, 2002). For low moi growth kinetics
analyses, SV5 titers were determined by plaque assays on CV-1 cell
monolayers as described previously (Wansley and Parks, 2002). For in
vivo experiments, viruses were concentrated by centrifugation through
a glycerol cushion (5 h; 25,000 RPM; SW28 rotor), and virus pelletswere
resuspended in a small volume of DMEM containing 0.75% BSA.
Transfection of reporter plasmids, IFN-I assays
Induction of the IFN-beta promoter in CL-7 cells was assayed using
a luciferase reporter plasmid (pBlux) as described previously (Wansley
and Parks, 2002). A pISRE-luc plasmid containing ﬁve copies of the
ISG54 ISRE element upstream of a TATA box and luciferase reporter
gene was used to measure induction of ISRE transcription. Six-well
dishes of CL-7 cells were transfected as described above using 1 mg
each of pISRE-luc and a β-galactosidase reporter plasmid. Twenty-four
hours post-transfection, cells weremock-infected or infected at anmoi
of 20 with rSV5-WT or P/V mutants. Fifteen hours post infection (pi),
culture media was supplemented for 6 h with or without 1000 U of
mouse IFN-β (PBL Biomedical Laboratories). Cells were harvested in
reporter lysis buffer, and normalized luciferase activity was calculated.
To directly assess the induction of mouse IFN, triplicate six-well
dishes of CL-7 cells weremock infected or infected at anmoi of 20with
rSV5 viruses. At 24 h pi, supernatants were harvested from infected
cells, and IFN-alpha and IFN-beta levels in media were analyzed by
ELISA as described by themanufacturer (PBL Biomedical Laboratories).
RNAse Protection Assay (RPA) for ferret IFN-beta gene expression
A ferret IFN-beta cDNA was generated from ferret ﬁbroblast RNA
using reverse transcription PCR with primers described previously
(Svitek and von Messling, 2007). PCR products were cloned into a
pGem7 plasmid and used to generate 32P-labeled riboprobes for an
RNAse protection assay (RPA) as described previously (Dillon and
Parks, 2007). Brieﬂy, six-well dishes of ferret lung ﬁbroblasts were
mock-infected or infected with rSV5-GFP or rSV5-P/V-CPI− at an moi
of 10 in triplicate. At 20 h pi, total RNA was isolated in Trizol reagent.
Following hybridization and RNAse digestion, samples were electro-
phoresed through a 6% polyacrylamide gel containing 9 M urea and
analyzed by autoradiography.
SDS-PAGE, Western blotting, cell viability assays, apoptosis,
and microscopy
For Western blotting, equivalent amounts of protein were loaded
onto 10% gels, transferred to nitrocellulose membranes and analyzed
with rabbit antisera to the SV5 P protein (Parks et al., 2002), cellular
STAT1 protein (clone 554, Santa Cruz Biotechnology), STAT1 phos-
phorylated on tyrosine residue 701 (pSTAT, BD Biosciences), or actin,
followed by HRP-conjugated secondary antibodies and visualization
by enhanced chemiluminescence and exposure to ﬁlm.
To quantitate SV5-induced cytopathic effect (CPE), triplicate six-well
dishes of ferret lung ﬁbroblasts were mock infected or infected with
rSV5-GFPorP/V-CPI− at anmoi of 10. At the indicated timespi, cellswere
trypsinized, and cell viability was determined by counting trypan blue-
negative cells. To quantitate the levels of annexin V staining, cells weremock infected or infected with rSV5-GFP or P/V-CPI− at anmoi of 10. At
the indicated times pi, cells were harvested with trypsin, stained with
Annexin V conjugated to phycoerythrin (BD Biosciences), and analyzed
using a FACScalibur ﬂow cytometer as described previously (Arimilli
et al., 2006). Microscopy experiments were performed on a Nikon
Eclipse ﬂuorescence microscope using a 20× lens. Images were cap-
tured using a QImaging digital camera and processed using QCapture
software. Exposure times were manually set to be constant between
samples.
Sections of lung and the entire heads of the ferretswere preserved in
10% neutral buffered formalin for at least 24 h. Following ﬁxation, heads
were decalciﬁed in Decalciﬁer-2 solution overnight and coronal sections
through the nasal cavity and calvarium, along with formalin ﬁxed
lungwere embedded inparafﬁn, routinely processed for histology, cut at
4–6 μm, stained with hematoxylin and eosin, and examined by light
microscopy. The heads of the mice were treated similarly.
In vivo growth analysis and antibody responses
All animals were cared for in accordance with the policies of the
Animal Care and Use Committee of Wake Forest University School of
Medicine. Six to eight week old female BALB/c mice were purchased
from Fredrick Cancer Research and Development Center (Fredrick, MD).
For growth analyses, mice were infected intranasally (i.n.) with 106 pfu
of puriﬁed rSV5-WT or P/V mutants in a volume of 10 μl as described
previously (Gray et al., 2003). At the indicated days pi, mice were
sacriﬁced, and the lungs were harvested by dissection, snap-frozen and
stored at −80 °C. Tissues were homogenized using a PowerGen 700
tissue homogenizer (Fisher Scientiﬁc) followed by clariﬁcation of tissue
debris at 450 g for 10min, and used inplaque assays as described above.
For antibody responses, mice were infected i.n. with the indicated
doses of concentrated rSV5-WT or P/V mutants. Booster inoculations
were carried outwith an equivalent amount of homologous virus. At the
indicated days pi, mice were bled from the tail vein, and the blood was
allowed to clot overnight at 4 °C before clariﬁcation by centrifugation.
For the SV5-speciﬁc ELISA, virus was puriﬁed by sucrose-gradient cen-
trifugation as described previously (Paterson et al., 1995), and protein
levels were determined by BCA. Plates were coated overnight at 4 °C
with 12.5 μg/ml of puriﬁed virus, and incubated with serial dilutions of
mouse sera at room temperature for 2 h. Afterwashingwith PBS/Tween
(0.02%), samples were incubatedwith HRP-conjugated anti-mouse IgG1
or IgG2a secondary antibodies for 1 h, followed by a ﬁnal washwith PBS/
Tween (0.02%) and incubation in the dark with TMB substrate solution
(Sigma) before determining absorbance values at 450 nm. Final titers
were expressed as the dilution of serum that yielded an absorbance of
one-half themaximal absorbance obtainedusingamonoclonal antibody
(4b) to SV5 HN protein run in parallel.
Four month old male ferrets were obtained from Marshall Farms
(North Rose, NY) and infected i.n. with the indicated doses of puriﬁed
rSV5-GFP or P/V-CPI− in avolumeof 50 μl. In vivo growth analyseswere
performed by harvesting the indicated regions of the respiratory tract
and using the homogenized tissues in a plaque assay as described
above. Ferret antibody responses were analyzed by withdrawing 1–
3ml of blood from the jugular vein on day 28 pi. Animalswere boosted
with an equivalent amount of homologous virus, and blood was col-
lected by cardiac puncture at the termination of the experiment (day
14 post boost). ELISAswere performed using clariﬁed sera as described
above except the secondary antibody was an anti-ferret IgG (Bethyl
Laboratories). Final antibody titers for ferret experimentswere deﬁned
as the dilution of serum that yielded an absorbance of two times the
absorbance obtained using serum from a naïve animal run in parallel.
To determine the levels of neutralizing antibody, clariﬁed serawere
serially diluted and incubated at room temperature for 30 min with
100 pfu of an rSV5 virus that expresses enhanced green ﬂuorescence
protein (rSV5-EGFP). This mixture was then added to MDBK cells and
incubated at 37 °C for 1 h. The inoculumwas replacedwith freshmedia,
427G.A. Capraro et al. / Virology 376 (2008) 416–428and cells were incubated for 24 h, followed by analysis of EGFP ex-
pression by ﬂuorescence microscopy. The neutralizing antibody (nAb)
titer is deﬁned as the lowest dilution of serum that yielded a 50%
reduction in EGFP expression as compared to cells infected with
100 pfu of rSV5-EGFP in the absence of serum.
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